Clinical Trials Logo

Invasive Breast Carcinoma clinical trials

View clinical trials related to Invasive Breast Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05177796 Withdrawn - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Start date: March 11, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether panitumumab and pembrolizumab in combination with standard of care chemotherapy before surgery (neoadjuvant) works to shrink tumors in patients with stage III-IV triple negative breast cancer. Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving panitumumab and pembrolizumab in combination with neoadjuvant chemotherapy may kill more tumor cells in patients with triple negative breast cancer.

NCT ID: NCT03238703 Withdrawn - Clinical trials for Invasive Breast Carcinoma

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

This pilot clinical trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells. Endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators may lessen the amount of estrogen made by the body.

NCT ID: NCT02856503 Withdrawn - Breast Cancer Clinical Trials

Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors

Start date: January 2019
Phase: Phase 1/Phase 2
Study type: Interventional

High-doses of Vitamin D (VD) may be used as targeted therapy against breast cancer. The investigators will assess the effect of high dose VD on the following biomarkers in the breast cancer cells: VDR, estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor 2 (Her2/neu), androgen receptor (AR), as well as epidermal growth factor receptor 1 (EGFR) and Ki-67, as markers of proliferation, and E-cadherin, a marker of invasion and metastasis.